Analysts Expect Viking Therapeutics Inc (VKTX) Will Announce Earnings of -$0.11 Per Share

Wall Street brokerages expect Viking Therapeutics Inc (NASDAQ:VKTX) to report ($0.11) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Viking Therapeutics posted earnings of ($0.22) per share in the same quarter last year, which suggests a positive year over year growth rate of 50%. The business is scheduled to issue its next earnings results on Wednesday, November 14th.

On average, analysts expect that Viking Therapeutics will report full year earnings of ($0.44) per share for the current year, with EPS estimates ranging from ($0.47) to ($0.41). For the next financial year, analysts forecast that the business will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.55) to ($0.39). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02).

Several brokerages have recently weighed in on VKTX. BidaskClub downgraded shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 3rd. William Blair reiterated a “market perform” rating on shares of Viking Therapeutics in a research note on Monday, October 1st. HC Wainwright set a $31.00 target price on shares of Viking Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 1st. Raymond James set a $43.00 target price on shares of Viking Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, September 19th. Finally, Roth Capital increased their target price on shares of Viking Therapeutics from $13.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, September 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Viking Therapeutics has a consensus rating of “Buy” and a consensus price target of $28.17.

Shares of VKTX traded down $0.75 during mid-day trading on Friday, hitting $14.51. 55,651 shares of the company’s stock were exchanged, compared to its average volume of 2,877,918. Viking Therapeutics has a fifty-two week low of $2.00 and a fifty-two week high of $24.00. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -18.81 and a beta of 2.81.

In related news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.90% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in the stock. Boxer Capital LLC lifted its position in Viking Therapeutics by 17.7% in the second quarter. Boxer Capital LLC now owns 3,750,000 shares of the biotechnology company’s stock valued at $35,588,000 after purchasing an additional 564,000 shares during the period. BlackRock Inc. lifted its position in Viking Therapeutics by 681.0% in the second quarter. BlackRock Inc. now owns 2,938,645 shares of the biotechnology company’s stock valued at $27,888,000 after purchasing an additional 2,562,356 shares during the period. Janus Henderson Group PLC acquired a new stake in Viking Therapeutics in the second quarter valued at about $19,552,000. Millennium Management LLC lifted its position in Viking Therapeutics by 99.1% in the first quarter. Millennium Management LLC now owns 1,399,370 shares of the biotechnology company’s stock valued at $6,115,000 after purchasing an additional 696,398 shares during the period. Finally, Opaleye Management Inc. lifted its position in Viking Therapeutics by 9.0% in the second quarter. Opaleye Management Inc. now owns 1,200,000 shares of the biotechnology company’s stock valued at $11,388,000 after purchasing an additional 99,200 shares during the period. Hedge funds and other institutional investors own 53.22% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

See Also: Short Selling – Explanation For Shorting Stocks

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply